Ginkgolide-Platinum(II) Complex GPt(II) Exhibits Therapeutic Effect on Depression in Mice via Upregulation of DA and 5-HT Neurotransmitters

Background: Depression is the 5th most prevalent disorder adversely affecting the health of humans worldwide. The present study evaluated the antidepressant effect of ginkgolide-platinum(II) complex in vivo in a mice model of CMS-induced depression.

Material/Methods: Depression was induced in mice by social isolation followed by chronic mild stress. After stress, the mice were assigned randomly to a model group, a 3 mg/kg group, a 6 mg/kg group, and a 12 mg/kg group. The mice in the 3 treatment groups were intraperitoneally injected with a single dose of 3.0, 6.0, or 12.0 mg/kg GPt(II) on day 11 of stress. The behavioral changes in mice were analyzed on day 21 of GPt(II) treatment by suspension and open field tests.

Results: The GPt(II) treatment significantly increased the numbers of crossings and rearings in CMS mice. Treatment of mice with GPt(II) significantly elevated dopamine, BDNF, and serotonin levels in hippocampus tissues. The CMS-mediated reduction of neuropeptide production in hippocampus tissues was significantly alleviated by GPt(II) treatment (P<0.05). The GPt(II) treatment suppressed the effect on CMS-induced elevated level of MAO-A in hippocampus tissues. Treatment with GPt(II) significantly repressed caspase-3 activation induced by CMS in the hippocampus tissues of mice. The GPt(II) treatment significantly (P<0.05) upregulated Hsp70 mRNA level in depression model mice. The levels of dopamine, serotonin, and BDNF were increased from 187.83±8.53, 289.65±10.76, and 7.98±1.87 ng/g, respectively, in the model group to 657.63±24.47, 720.54±28.09, and 22.56±3.11 ng/g, respectively, in the 12 mg/kg GPt(II) treatment group.

Conclusions: GPt(II) treatment significantly relieved characteristics of depression in the mice through upregulation of neurotransmitter, neuropeptide, and Hsp70 expression. Moreover, GPt(II) downregulated monoamine oxidase-A levels in the mouse hippocampus tissues. Therefore, further research is warranted on the possible therapeutic effect of GPt(II) in the treatment of depression.

MeSH Keywords: Depression • Monoamine Oxidase • Neuropeptide Y

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/922052
Background

Depression is the 5th most prevalent disorder adversely affecting the health of humans worldwide [1,2]. It is a chronic neurological disorder characterized by frequent recurrence, high prevalence, and low rate of treatment success [1,2]. The etiology of depression involves multiple factors, including genetics, social environment, personality, and endocrine secretions involved in development of this disorder. The disease is associated with suppression of neurotransmitters like dopamine and serotonin, as well as reduction of neurotrophic factors such as neurotrophin-Y in brain tissues [3–5]. Thus, up-regulation of dopamine, serotonin, and neurotrophin-Y has immense importance for the treatment of depression. Heat shock protein 70 (Hsp70) induces most conserved pathways of cellular response to different types of oxidative stress [6]. Hsp70 is immediately induced during cell stress to regulate homeostasis [7,8]. In animal models of nervous system injury, the Hsp70 level is elevated and acts as a protective agent [8]. Studies have revealed that Hsp70 alleviates depression through regulation of glucocorticoid receptor activity [9]. The defect in the Hsp70 gene due to deletion of 162-base from 5'-flanking region is responsible for development of depression [10]. The mechanism of antidepressant activity of some therapeutic compounds involves upregulation of Hsp70 expression [11].

Panax ginseng consists of several plant species belonging to the Panax genus and Araliaceae family found in north-eastern Asia. In Japan and Korea, P. ginseng has been used in traditional medicine as a revitalizing agent [12]. Later on, triterpeneoid compounds like ginkgolides were isolated from P. ginseng, which demonstrated neuroprotective activities [12]. The inorganic complexes of platinum have been found to possess various biological properties, but have the limitation of inducing adverse effects [13,14]. The modification of these platinum complexes led to avoidance of adverse effects and increase of biological activity [13,15]. Complexes of platinum were synthesized by linking it to the natural compound and screening for efficacy in treating various diseases [16,17]. The complex of jatrorrhizine, an active constituent of Tinospora capillipes Gagnep with platinum has shown a broad spectrum of biological properties [18,19]. In the present study, we assessed the antidepressant effect of ginkgolide-platinum(II) complex GPt(II) in vivo in the mouse model of CMS-induced depression.

Material and Methods

Animals

Fifty C57BL/6 mice (7–8 weeks old) were obtained from the Shanghai Slac Laboratory, Shanghai, China. The mice were acclimated to the facilities in the Animal Center laboratory for 7 days before experiments were started. The mice were housed with 12/12 h light/dark cycle and provided free access to food and water. The study was approved by the Animal Ethics Committee, Xinxiang Medical University (Xinxiang, China; Approval number MU/2017/0027). The procedures were performed in accordance with the guidelines of the National Institutes of Health, China.

Mouse depression model preparation and treatment

The mouse depression model was prepared using social isolation in combination with chronic mild stress. The mice were individually housed in cages and daily subjected to stress for 3 weeks. The methodology of stress was: a) 24-h fasting; b) 24-h water deprivation; c) 24-h cage tilting at 30°; d) 1-min pinching of tail; e) 2-h restraint in a 10×2.5 cm fixator; f) 3-min continuous soaking in water at 17°C; g) 3-min continuous soaking in water at 40°C; and h) alteration of day with night. Following stress, the mice were randomly assigned to the model group, 3 mg/kg group, 6 mg/kg group, and 12 mg/kg group. Each group contained 10 mice, and 10 mice without stress treatment were used as controls. The mice in the 3 treatment groups were given a single dose of 3.0, 6.0, or 12.0 mg/kg GPt(II) on day 11 of stress, administered intragastrically in normal saline. The model and control mice were injected with equal volumes of normal saline at the same time. The behavioral changes in mice were analyzed on day 21 of GPt(II) treatment.

Suspension test

A black plexiglass box was used to determine immobility time for each mouse after suspension. Briefly, the mouse tail at the distal end was fixed with the crossbar kept at 30 cm height from the base. The mice were continuously kept in inverted position with head down for 6 min. The mice were adapted for 2 min, followed by measurement of immobility time.

Open field test

The test was conducted on day 21 of GPt(II) treatment using a 100×100×50 cm box. The 4-sided box contained 25 equilateral squares, and each mouse was put on the center square. The activity of each mouse in the box was monitored carefully to count the numbers of crossings and rearings during 5 min.

ELISA assay for dopamine, serotonin, and BDNF levels

Five mice from each group were subjected to exsanguination following anesthesia (pentobarbital anesthesia at 35 mg/kg) on day 21 of GPt(II) injection. The brain tissues were carefully excised, washed with saline and subjected to homogenization. The homogenized tissues were centrifuged at 4°C for 15 min at 13,000×g to collect supernatant. The levels of...
dopamine, serotonin, and BDNF in the supernatant were analyzed using ELISA kits.

**Western blot analysis**

The mice were sacrificed by exsanguination following anesthesia on day 21 of GPt(II) injection to excise the brain tissues. The mice were lyzed, homogenized, kept for 40 min on ice, and centrifuged at 4°C for 40 min at 12,000×g. The supernatant was mixed with loading buffer 5X consisting of Tris-hydrochloric acid (60 mM, at pH 6.8), SDS (2%), bromophenol blue (0.1%), trihydroxy propanol (25%), and β-mercaptoethanol (14 mM). The mixture was boiled in a water bath for 20 min, followed by separation of proteins on SDS-PAGE using electrophoresis. The proteins were subsequently transferred onto PVDF membranes, which were blocked on incubation with dry milk (5%) for 1.5 h. The membranes were incubated overnight with primary antibodies for anti-neuropeptide, anti-MAO-A, anti-caspase-3, and anti-Hsp70 at 4°C. After washing 3 times in PBST, the membranes were incubated with HRP-labeled rabbit anti-mouse secondary antibodies at room temperature for 2 h. The illumination of bands was performed using an ECL system (Santa Cruz Biotechnology) and the blots were normalized to β-actin.

**Reverse transcription-polymerase chain reaction (RT-PCR)**

The mice were sacrificed by exsanguination following anesthesia on day 21 of GPt(II) injection. Right hippocampus tissues were excised, and frozen in liquid nitrogen until further analysis. The total RNA from hippocampus tissues was isolated by treatment with TRIzol reagent. The RNA was subjected to reverse transcription into cDNA using a reverse transcriptase with an RNase inhibitor and a 2×RT buffer (M-MLV reverse transcriptase; Promega, Madison, WI, USA). The cDNA was used as a template for the amplification of β-actin and caspase-3 by polymerase chain reaction (PCR). The cycling conditions used were: activation of polymerase at 95°C for 1 min, followed by 35 cycles of denaturation at 95°C for 30 s, primer extension at 58°C for 30 s, and melting at 72°C for 30 s, followed by final extension at 72°C for 5 min. The primers used were:

- **HSP-70**: forward, 5'-GCTGGTACACCTCCTCGT-3' and reverse, 5'-TGGATCTGCGCCTTGCC-3';
- **MAO-A**: forward, 5'-ATTGGAGCGGGGATTCAGGAT-3' and reverse, 5'-AGGTTGAATGCACCAAGGGAT-3';
- **caspase-3**: forward, 5'-AACGAAGGGACCTGTGG-3' and reverse, 5'-TCTTGCATGACATGACATG-3'.

The cycling conditions used were: activation of polymerase at 93°C for 10 min, then 93°C for 25 s and 58°C for 25 s. The changes in RNA by relative fold change were normalized to β-actin and calculated by 2^DDCq method.

**Immunohistochemical analysis**

The mice were sacrificed by exsanguination following anesthesia on day 21 of GPt(II) injection to excise the brain tissues. The tissues were immediately fixed in 4% paraformaldehyde overnight. The tissues were washed, dehydrated using a gradient ethyl alcohol series, and then embedded in paraffin. The paraffin-embedded brain tissues were cut into 3-µm sections and treated with hydrogen peroxide (3%) for 20 min. The tissue sections were incubated for 2 h with mouse anti-rabbit polyclonal antibodies against Hsp70 at 4°C. Then, the sections were incubated at room temperature with biotinylated goat anti-rabbit IgG secondary antibody for 1.3 h. PBS washing was followed by incubation for 1 h with horseradish peroxidase. The tissues were then treated with DAB solution followed by hematoxylin counterstaining, and then were examined under a light microscope (magnification ×400).

**Statistical analysis**

Data are expressed as mean ± standard deviations (mean±SD). Comparisons between groups were made using one-way analysis of variance (ANOVA) and t test. Data analysis was performed using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). Differences were regarded as statistically significant at P<0.05.

**Results**

**Improvement of locomotor activity by GPt(II) in CMS mice**

Locomotor activity was significantly reduced in mice after 21 days of CMS relative to the sham control group. CMS significantly decreased the numbers of crossings in mice (P<0.05) relative to the sham group (Figure 1A). The numbers of rearings was also significantly (P<0.05) lower in CMS mice relative to controls (Figure 1B). However, GPt(II) treatment significantly increased the numbers of crossings and rearings (P<0.05) in CMS mice, and the effect was in dose-dependent. The CMS-mediated reduction in numbers of crossings and rearings was completely reversed in the 12.0 mg/kg GPt(II) treatment group.

**GPt(II) promotes dopamine and serotonin expression in mouse hippocampus tissues**

ELISA results showed that CMS exposure significantly (P<0.05) suppressed dopamine and serotonin in hippocampus tissues of mice (Figure 2). Treatment with 3.0, 6.0, or 12.0 mg/kg GPt(II) significantly elevated dopamine and serotonin levels in the hippocampus tissues in a dose-dependent manner. The BDNF level was also significantly (P<0.05) suppressed by CMS in hippocampus tissues relative to the sham group (Table 1). However, GPt(II) treatment significantly prevented CMS-mediated suppression of BDNF level at 3.0 (P<0.01), 6.0 (P<0.02), and 12.0 (P<0.05) mg/kg doses.
GPt(II) increased neuropeptide-Y level in mouse hippocampus tissues

The level of neuropeptide in mouse hippocampus tissues was significantly suppressed (P<0.05) by CMS relative to the sham group (Figure 3). However, GPt(II) treatment significantly (P<0.05) alleviated CMS-mediated reduction of neuropeptide-Y in the hippocampus tissues of mice. The CMS-mediated suppression of neuropeptide-Y level was significantly alleviated by treatment with 3.0, 6.0, and 12.0 mg/kg GPt(II).

Inhibition of MAO-A by GPt(II) in the hippocampus of mice

The CMS caused a marked elevation in MAO-A level in the mouse hippocampus tissues relative to the sham group (Figure 3). The GPt(II) treatment suppressed the CMS-induced elevated level of MAO-A in mouse hippocampus tissues. The level of MAO-A protein and mRNA induced by CMS was significantly suppressed by GPt(II) treatment at 3.0 (P<0.01), 6.0 (P<0.02), and 12.0 (P<0.05) mg/kg doses.

Inhibition of caspase-3 activation by GPt(II) in mouse hippocampus

The caspase-3 level was significantly elevated (P<0.05) in the hippocampus of mice by CMS relative to the sham control group (Figure 5). Treatment with GPt(II) significantly repressed caspase-3 activation induced by CMS in the hippocampus tissues of mice. The suppression of CMS-mediated caspase-3 level by GPt(II) treatment in mice was significant at 3.0 (P<0.01), 6.0 (P<0.02), and 12.0 (P<0.05) mg/kg doses compared to the untreated group.
Figure 3. Effect of GPt(II) on neuropeptide-Y level in hippocampus tissues. The mice were subjected to CMS and then intraperitoneally injected with 3.0, 6.0, or 12.0 mg/kg doses of GPt(II). The neuropeptide-Y level was determined using (A) Western blot assay and (B) data were quantified. * P<0.05, and ** P<0.05 vs. sham control.

Figure 4. Effect of GPt(II) on MAO-A level in mouse hippocampus. CMS mice were intraperitoneally injected with 3.0, 6.0, or 12.0 mg/kg doses of GPt(II). The MAO-A (A) mRNA and (B) protein expression was detected by RT-PCR and Western blot assay in hippocampus tissues. * P<0.05, and ** P<0.05 vs. sham control.

Figure 5. Effect of GPt(II) on caspase-3 activation induced by CMS in mice. CMS mice were intraperitoneally injected with 3.0, 6.0, or 12.0 mg/kg doses of GPt(II). The caspase-3 (A) mRNA and (B) protein expression was detected by RT-PCR and Western blot assay in hippocampus tissues. * P<0.05, and ** P<0.05 vs. sham control.
ANIMAL STUDY

Also called neuroendocrine polypeptide, regulates excitability of neurons during signal transmission [28]. The pathogenesis of depression is determined by secretion of MAO-A enzyme, which catalyses reduction of monoamine levels [29]. It is believed that overproduction of MAO-A can be inhibited by increasing the level of Hsp70 in hippocampal tissues [30]. The upregulation of Hsp70 by therapeutic molecules has been found to exhibit cytoprotection effects in various cells [31]. In the present study, the neurotransmitter (dopamine, BDNF, and serotonin) level decreased in the hippocampi of CMS mice. The inhibitory effect of CMS on neurotransmitter level in the mouse hippocampus was significantly alleviated by GPT(II) treatment. GPT(II) treatment also alleviated CMS-mediated reduction of neuropeptide in mouse hippocampus tissues. CMS exposure markedly increased monoamine oxidase-A secretion and elevated production of Hsp70 in the mouse hippocampus tissue. These results suggest that the antidepressant effect of GPT(II) in mice involves suppression of MAO-A and upregulation of Hsp70 production. The behavioral assays showed that characteristics of depression were effectively relieved in mice after treatment with GPT(II) treatment. The loss of hippocampus cells like neurons and glial cells has been observed in post-mortem brain samples of patients with depression, which indicates apoptosis activation [32]. Neuronal apoptosis is also reported in the cerebral cortex of animals exposed to chronic stress [32]. The apoptotic process clearly contributes to reduction of hippocampal volume and development of depression [33]. The cellular apoptosis is effectively caused by activated caspase-3 [34]. In the present study, hippocampus tissues of CMS-exposed mice markedly overexpressed activated caspase-3 compared to the sham group. The increased caspase-3 serves as a marker of apoptosis activation in the CMS mouse hippocampus tissues. Fortunately, GPT(II) treatment
effectively suppressed CMS-mediated activation of caspase-3 in hippocampus tissues. Stress-induced cell apoptosis is effectively inhibited by Hsp70 in various types of tissues [35]. It was reported that Hsp70 targets ROS accumulation, alleviates the toxicity of amino acids, and inhibits apoptosis in various stressed tissues [36]. Therefore, GPT(II) may partly exhibit antidepressant effect by inhibiting apoptosis in hippocampus tissues through promotion of Hsp70 production.

References:

4. Teo CH, Soga T, Parhar IS: Brain beta-catenin signalling during stress and depression. Neurosignals, 2018; 26: 31–42
9. Rajapandi T, Greene LE, Eisenberg E: The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol Chem, 2000; 275: 22597–604
34. Lee AL, Ogle WD, Sapolsky RM: Stress and depression: Possible links to neuron death in the hippocampus. Bipolar Disord, 2002; 4: 117–28

Conclusions

GPT(II) treatment effectively relieved characteristics of depression in the mice through upregulation of neurotransmitter, neuropeptide, and Hsp70 expression. Moreover, GPT(II) downregulated monoamine oxidase-A level in the hippocampus tissues of mice. Further research is needed to elucidate the possible role of GPT(II) in the treatment of depression.